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LETTERS TO THE EDITOR
Nuclear factors,
hs1,2 enhancer and
IgA nephropathy
To the Editor: Within the immunoglobulin H (IgH)
locus, a minisatellite region of 53 bp is duplicated in one
allele of the hs1,2 enhancer lying beside the 1 gene that
encodes IgA1 [1]. In IgA nephropathy patients, this allele
is associated with a severe evolution leading to renal fail-
ure [2, 3]. This duplication increases the transcriptional
strength of the 1 hs1,2 enhancer and results in a higher
rate of IgA1 production in patients, thus likely yielding
heavier IgA1 kidney deposits. Using electrophoretic mo-
bility shift assay, we have found that this minisatellite
region carries potential transcription factor-binding site
(Fig. 1). Despite that it exhibits putative nuclear factor-
kappa B (NF-B)-, Sp-1-, NF-1- and AP-1-like-binding
sites [1], antibody supershift experiments did not show
the involvement of P50, P52, P65, rel-b, c-rel, c-fos, c-jun,
NF-1 and AP-1 nuclear factors (data not shown). Thus,
still unknown nuclear factors bind to the minisatellite re-
gion of the hs1,2 enhancer and might boost the transcrip-
tion of the 1 gene. Their further identification might be
Fig. 1. The minisatellite region in the hs1,2 enhancer had several DNAof interest to improve our knowledge in the course of
binding sites. Nuclear extracts (10 g) were prepared from RPMI and
evolution of IgA nephropathy toward renal failure. U266 (myeloma cell lines) and IM9 and JI cells (B cell lines). Reactions
were analyzed on a 6% polyacrylamide gel. Control line contained P32-
probe alone. Complexes (C) formed between nuclear extract proteinsBarbara Bessette, Laurence Guglielmi, Michel Cogne´,
and labeled probe are indicated with arrows.and Yves Denizot
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dence is higher in patients with cuffed catheters compared Dual blockade of
with those with non-cuffed catheters. Correctly, in this
paper, Pastan, Soucie, and McClellan describe several fac- renin-angiotensin system
tors that might explain the increased risk of death in pa-
tients with venous catheters, but title and conclusion are
To the Editor: Dr. Laverman et al indicated in theirvery strong [1].
well-designed study recently published in Kidney Interna-Statistics can help us understand the laws of nature,
tional that dual renin-angiotensin system (RAS) blockadebut is not the nature law. We would like to report our
may be more effective to reduce proteinuria compared toexperience of 84 months of follow-up in the successful
monotherapy in patients with non-diabetic renal diseasesuse of cuffed central venous catheters in 88 patients in
[1]. Angiotensin II is generated via non-angiotensin-con-chronic hemodialysis in Lucania (Italy) from January 1992
verting enzyme (ACE) pathways in the human kidney [2],
to December 1998 [2]. Our study demonstrated that only arteries [3], and veins. The combination of ACE inhibitors
10 episodes of catheter-related major sepsis (one case in and angiotensin II antagonists could result in more perfect
every 305 months/patient) were registered and resolved blockade of the RAS and optimal inhibition of progressive
by antibiotic therapy without catheter removal [3]. During pathologic processes in these tissues. However, the effect
follow-up, 29 patients died (the mortality rate was 5% per of combination therapy compared to monotherapy on
year, half of the rate reported for the general hemodialysis blood pressure remains to be interpreted with caution
population in Italy) and not one of the deaths was reported in their study. The trough blood pressure measured with
to be from an infection-related cause [2]. Our excellent great care was used as an index of blood pressure control.
results may be due to two principal factors. First, a neph- During monotherapy, the patients took the study medi-
rologist is always present in the dialysis room to follow- cation once daily in the morning. On the other hand,
lisinopril was taken in the evening and losartan was takenup on all patients. Second, venous catheters are treated
in the morning during the period of combined treatment.with the same care and asepsis required in the manage-
Since lisinopril might have been still active and affectedment of peritoneal catheters [3].
“trough” blood pressure levels downward, it is not fair toFlow performances and dialysis dose can be slightly
compare blood pressure lowering effect of monotherapyreduced (5 to 6%) when compared with arteriovenous
with that of combined treatment. Taking into acccountfistula. If regular assessment of dialysis performance is
their poor prognosis, dual RAS blockade may be applieddecreased by reduced blood flow with catheter use, length-
to patients with critical organ damage such as markedening dialysis time may represent a simple and efficient
proteinuria, renal insufficiency, diabetic complicationstool to compensate for reduced performances.
[4], and heart failure. However, the use of dual RASIn conclusion, venous catheters are a valid alternative
blockade for simple blood pressure control warrants firm
in critical patients, even when considering the potential
evidence that this therapy surpasses monotherapy at its
complications and risks. Of note, the first venous catheter maximally effective dose or the other combination regi-
in Lucania was inserted in January 1992 into a female men such as single RAS blockade and diuretics or cal-
patient who did not have and other available vascular cium channel blocker.
access and after failed peritoneal dialysis. This patient is
still living 11 years later and continues to be dialyzed with Atsuo Goto
Tokyo, Japanthe same catheter [2].
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